New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease

Estimated Time
1.00 hour

Release Date
May 31, 2023

Expiration Date
May 30, 2024

Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table TalkTM episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations. In this exclusive, Special Edition Med Table TalkTM episode, our academic and community oncology experts will explore the following key points:

  • Emerging evidence, rationale, and clinical implications for the use of CAR T-cell therapy in the early versus late stages of relapse, with insights into how disease biology and overall outcomes differ among these patient populations(eg, high-risk, early relapse, TCE, etc).
  • Best practices for fostering interprofessional collaboration between cellular therapist facilities and community oncology practice settings, focusing on strategies to enhance teamwork as a means to enhance patient care and optimize the use of CAR T-cell therapy.
  • Approaches to ensure timely referral and initiation of treatment through clinical trials, specifically focusing on reaching patients from underrepresented communities, facilitating access and representation to CAR T-cell therapies in clinically appropriate patients.


Accreditation and Disclosure Information

Target Audience
This activity is intended for hematologic oncology clinicians, nurses, pharmacists, pathologists, and other members of the multidisciplinary and interprofessional care team who diagnose and/or treat individuals with multiple myeloma.

Educational Objectives
After completing this activity, the participant should be better able to:

  • Evaluate the rationale and significance of CAR T-cell therapies in addressing an unmet need for response durability in early versus late relapsed/refractory multiple myeloma.
  • Explain the clinical implications for current and emerging evidence for the earlier use of CAR T-cell therapy in MM, particularly among those experiencing early relapse after first-line therapy or after triple-class exposure.
  • Design practical approaches for the optimal use and timing of CAR T-cell therapies in practice, with considerations to promoting clinical trial enrollment and access to underrepresented communities.

Program Agenda
Part 1: Current Paradigms and Unmet Needs in the Management of Multiple Myeloma

  • Introduction
  • Appropriate risk stratification and prognosis as a means to guide MM treatment selection
  • Current national guideline recommendations and FDA-approved indications for the treatment of early vs. late relapsed/refractory MM
  • Rationale for earlier use of CAR T-cell therapies
  • Community Oncologist Perspective and Panel Discussion

Part 2: Emerging Evidence for CAR T-cell Therapy Use Earlier in the MM Treatment Paradigm

  • Clinical data for CAR T-cell therapies in earlier stage disease, TCE and/or early frontline relapse
  • Clinical implications of data and emerging evidence
  • Community Oncologist Perspective on Data
  • Early identification in determining the optimal candidates for CAR T-cell therapy
  • Key Points

Accreditation, Support and Credit

Joint Accreditation with Commendation LogoIn support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and no contact hour in the area of pharmacology.

Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-045-H01-P
Type of Activity: Knowledge

AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 30, 2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Support Statement
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, NY

Saad Z. Usmani, MD, MBA, FACP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.
Research Grant: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda

Melody Smith, MD, MS
Assistant Professor of Medicine
Stanford University, Department of Medicine
Division of Blood & Marrow Transplantation and Cellular Therapy
Stanford, CA

Melody Smith, MD, MS, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Bristol Myers Squibb

Krina K. Patel, MD, MSc

Associate Professor
Lymphoma/Myeloma Department
The University of Texas MD Anderson Cancer Center
Houston, TX

Krina K. Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Curio Bioscience, Janssen, Karyopharm, Legend Biotech, Merck, Oncopeptides, Pfizer, Precision Biosciences
Research Grant: AbbVie, Allogene, Arcellx, Bristol Myers Squibb, Celgene, Cellectis, Janssen, Nektar, Poseida, Precision Biosciences, Takeda

Sanjay Sharma, MD
St Jude Crosson Cancer Institute
Providence OC Cancer Institute
Fullerton, CA

Sanjay Sharma, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau: AstraZeneca, Bristol Myers Squibb, EMD Serono, Guardant Health, Merck

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact MLI at

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website:

About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

MLI logo

Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.